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ABSTRACT
Chemotherapeutic treatment of breast cancer is based on maximum tolerated 
dose (MTD) approach. However, advanced stage tumors are not effectively eradicated 
by MTD owing to suboptimal drug targeting, onset of therapeutic resistance and 
neoangiogenesis. In contrast, “metronomic” chemotherapy is based on frequent 
drug administrations at lower doses, resulting in neovascularization inhibition and 
induction of tumor dormancy. Here we show the potential of H-ferritin (HFn)-mediated 
targeted nanodelivery of metronomic doxorubicin (DOX) in the setting of a highly 
aggressive and metastatic 4T1 breast cancer mouse model with DOX-inducible 
expression of chemoresistance. We find that HFn-DOX administered at repeated doses 
of 1.24 mg kg−1 strongly improves the antitumor potential of DOX chemotherapy 
arresting the tumor progression. We find that such a potent antitumor effect is 
attributable to multiple nanodrug actions beyond cell killing, including inhibition of 
tumor angiogenesis and avoidance of chemoresistance. Multiparametric assessment 
of heart tissues, including histology, ultrastructural analysis of tissue morphology, 
and measurement of markers of reactive oxygen species and hepatic/renal conditions, 
provided evidence that metronomic HFn-DOX allowed us to overcome cardiotoxicity. 
Our results suggest that HFn-DOX has tremendous potential for the development of 
“nanometronomic” chemotherapy toward safe and tailored oncological treatments.
INTRODUCTION
Over the past decades, cytotoxic chemotherapeutics 
have dominated the systemic management of cancer 
according to the “maximum tolerated dose” (MTD) 
paradigm [1, 2]. MTD therapy requires that patients are 
administered with single dose or short courses of the 
highest tolerable dosage of a drug in order to achieve the 
best therapeutic efficacy. Due to low tumor selectivity, 
MTD treatments cannot be protracted in order to allow 
recovery of healthy tissues and to reduce myelosuppression 
associated with pulsed drug doses [3]. In fast-growing or 
metastatic tumors, during these therapeutic breaks, a burst 
in cancer cell proliferation accompanied by manifestation 
of chemoresistance and accelerated angiogenesis are likely 
[4, 5]. Hence, a reappraisal of advanced-stage cancer 
management is ongoing, moving from the “maximum 
tolerable” to the “minimum effective” dose paradigm [6]. 
Indeed, cytotoxic agents administered at low dosages are 
expected to allow protracted treatments and have been 
suggested to up-regulate antiangiogenic factors such as 
thrombospondin-1 and to inhibit vascular endothelial 
growth factor and platelet-derived growth factor [2, 7].
The first clinical trials using low-dose metronomic 
(LDM) chemotherapy were conducted for breast, 
prostate, gastrointestinal, renal and pancreatic cancers, 
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as well as refractory melanoma [8–10]. This regimen 
is based on a lower dose of drugs administered 
more frequently, without the need of extensive 
interruptions [2, 11]. While the conventional dose-
dense chemotherapeutic setting is suggested to act by 
targeting the proliferating tumor cells [12], LDM is 
presumed to affect the vasculature growth and repair [8, 
13], to reduce systemic toxicity and myelosuppression, 
and to improve the stimulation of the host immune 
system against the tumor [1, 4]. However, several 
limiting factors remain for LDM in order to displace 
MTD treatments in clinical practice, including 1) low 
drug accumulation at tumor site [14], 2) controversial 
effectiveness against chemoresistance in advanced 
metastatic cancers [15], and 3) acquired resistance after 
prolonged treatment [16].
Recent advances in nanotechnology could offer 
groundbreaking solutions to improve the effectiveness of 
LDM chemotherapy, by taking advantage of the unique 
targeting efficiency of engineered nanocarriers [17]. In 
the present work, we propose a new concept of low dose 
“nanometronomic” (LDNM) chemotherapy. In principle, 
it is possible to obtain a prolonged antitumor effect with 
LDNM by means of multitasking nanocarriers that 
deliver lower dose of drug selectively to the growing 
tumor, inhibit the neovascularization process and prevent 
chemoresistance. Doxorubicin (DOX) is an excellent 
pilot drug for use in a LDM regimen [18], as its great 
anticancer efficacy is notoriously dose-limited by severe 
systemic side effects above all long-term cardiotoxicity 
with different severity grades from reduction in left 
ventricular ejection fraction (LVEF) to severe congestive 
heart failure [19, 20]. Liposomal anthracyclines, 
including pegylated liposomal doxorubicin (pl-DOX), 
have been introduced in clinical practice to enhance 
the therapeutic index and to avoid cardiotoxicity of 
these drugs thanks to higher accumulation of DOX 
in the tumor with reduced concentration in off-target 
organs [21]. However, meta-analyses of several clinical 
trials comparing pl-DOX to conventional DOX have 
demonstrated reduced (but not annulled) cardiotoxicity 
of pl-DOX, without improvement in progression-free 
or overall survival in advanced breast cancer (BC) 
[22]. Therefore, improving the therapeutic index of 
DOX remains an open challenge. As an ideal DOX 
nanocarrier for our LDNM study, we used H-Ferritin 
(HFn) nanocages, recently proposed as a promising 
bionanoparticle for cancer targeting [23] owing to its 
affinity for transferrin receptor 1 (TfR-1), which is 
constitutively overexpressed in primary and metastatic 
cancer cells [24]. HFn-DOX complex was recently 
demonstrated to overcome chemoresistance by actively 
promoting DOX nuclear translocation in vitro [25, 26] 
and was tested as a MTD treatment of a DOX-sensitive 
BC animal model with encouraging results [27].
RESULTS
In vitro uptake and cytotoxicity of HFn-DOX in 
4T1 breast cancer cells
The 4T1 cell line (4T1-L) was selected as in vitro 
and in vivo BC model for three main reasons: 1) tumor 
aggressiveness due to 4T1 genetic patterning, which 
results in high level of proliferation, migration and 
invasiveness; 2) basal expression of MDR-1 transporter, 
which switches into overexpression upon treatment 
with DOX resulting in chemoresistance [28]; 3) stable 
luciferase expression, which allowed us to follow the 
tumor progression and metastases. 4T1-L cells were 
first treated with FITC-labeled HFn (FITC-HFn) [25] to 
investigate the nanoparticle-cell interaction. Cells were 
incubated with FITC-HFn for 15 min, 1, 3 and 48 h, and 
analyzed by confocal microscopy to evaluate the uptake 
and intracellular trafficking. HFn was quickly internalized, 
since it was recovered inside the cell cytoplasm after only 
15 min of incubation, and it continued accumulating in 
the cytosol until 3 h (Figure 1A). The intracellular signal 
intensity decreased after 48 h probably due to ferritin 
disassembly, consistent with previous evidence [25]. HFn 
was found partly compartmentalized in early endosomes 
and partly free in the cytosol (Supplementary Figure 1), 
while the absence of colocalization with lysosomes, Golgi 
and transferrin (Tf) marker suggested that HFn did not 
follow lysosomal degradation, elimination or recycling, 
respectively, in agreement of previous evidence [25]. 
Binding assays with HFn at 20 or 100 μg mL−1 confirmed 
a dose-dependent recognition of tumor cells (Figure 1B).
4T1-L cells were treated with DOX or HFn-DOX 
at increasing concentrations of DOX to assess cell 
proliferation, cell death, DNA damage and nuclear DOX 
accumulation. Proliferation was arrested for at least 72 h 
after treatment with 1 μM HFn-DOX, while DOX reduced 
cell proliferation for 24 h only, suggesting the onset of 
chemoresistance upon incubation with DOX (Figure 
1C). Cell viability was evaluated by incubating the cells 
with 0.01, 0.1 and 1 μM DOX or HFn-DOX for up to 
72 h. Results reported in Figure 1D show that inhibition 
of BC cell viability using HFn-DOX was significantly 
higher than that after treatment with DOX. Such a drop 
in viability was ascribed to a remarkable increase in cell 
death (Figure 1E). Treatment with 0.01 μM HFn-DOX 
caused pronounced apoptosis and necrosis induction and 
double strand breaks in contrast to DOX (Figure 1F). It 
can be assumed that the increase in cytotoxicity of HFn-
DOX resides in the efficiency of HFn in promoting DOX 
nuclear translocation (Figure 1G), as already described 
for different tumor cell lines [25, 26]. Quantitative 
fluorescence analysis of confocal images gave a nuclear 
DOX concentration of 15.2 and 9-fold higher than that 
detected in cultures treated with DOX at 0.1 and 1 μM, 
respectively (Supplementary Figure 2).
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Figure 1: In vitro activity of HFn-DOX nanocages toward tumor cells. a. Intracellular localization of HFn nanoparticles. Confocal 
microscopy merged images of 4T1-L cells, incubated for 15 min, 1, 3 and 48 h at 37 °C with 100 μg mL−1 of FITC-labeled HFn (green). Nuclei 
were stained with DAPI (blue). Scale bar: 10 μm. b. HFn binding toward 4T1-L breast cancer cells. 4T1-L cells were incubated 2 h at 4 °C 
with FITC-labeled HFn (20 and 100 μg mL−1) and then processed for flow cytometry. Untreated cells were used as control to set the positive 
region. c. Proliferation profiles of cells treated with 1 μM DOX or HFn-DOX for up to 72 h. Untreated cells are used as control. Values are 
mean of six replicates ± SE. d. Viability of cells treated with free or nanoformulated DOX. 4T1-L cells were treated with 1, 0.1, and 0.01 μM 
DOX or HFn-DOX for up to 72 h. Viability was assessed by measuring the conversion of MTT into formazan, normalized on cell proliferation 
of untreated cells. Statistical significance vs. CTRL #P<0.05, ##P<0.005; Statistical significance vs. DOX *P<0.01; **P<0.005. e. Cell death 
assay using DOX or HFn-DOX. 4T1-L cells were treated with 1, 0.1, and 0.01 μM DOX or HFn-DOX for 3 or 24 h. Cell death was assessed 
on the basis of the exposure to Annexin V, evaluated by flow cytometry. Untreated cells were used to set region of positivity. Values are mean of 
three replicates ± SE. Statistical significance vs. DOX *P<0.005; **P<0.0005. f. Double-strand break of DNA after DOX exposure. Confocal 
microscopy images of 4T1-L cells incubated with 0.01 μM DOX or HFn-DOX. Anti-γH2A.X antibodies were used to reveal the DNA double-
strand breaks (DSB; yellow). Nuclei were stained with DAPI (blue). Scale bar: 10 μm. g. Doxorubicin release inside the nuclear compartment. 
Confocal microscopy images of 4T1-L cells incubated with 0.1 μM DOX or HFn-DOX and with 1 μM DOX for 3 h at 37 °C. DOX signal is 
represented in magenta, while DOX degradation product in green. Scale bar: 10 μm.
Oncotarget8386www.impactjournals.com/oncotarget
In vivo targeting and biodistribution of HFn 
nanocarrier
An orthotopic 4T1 metastatic BC model was 
obtained by implanting 4T1-L cells (105 cells) 
subcutaneously in the mammary fat pad of female 
Balb/C mice [29]. This murine tumor was reported 
to metastasize primarily, yet not exclusively, by a 
hematogenous route leading to metastatic spread to lung, 
liver and lymph nodes [30]. The reliability of the model 
was confirmed by following tumor progression and 
early onset of metastases by bioluminescence intensity 
(BLI) imaging over 20 days (Supplementary Figure 
3A). Histopathological analysis performed on excised 
tumors confirmed that the primary mass was indeed 
derived from epithelial cancer cells without undesired 
morphological alterations (Supplementary Figure 3B). 
4T1 mice were injected into the tail vein with Alexa 
Fluor660-labeled HFn (AF660-HFn) at 5 μg kg
−1 [31] 
and monitored by live fluorescence imaging at 1, 2, 24 
and 48 h. An intense epifluorescence signal (Epf) at the 
bladder was detected within the first 2 h, which however 
disappeared after 24 h (Figure 2A and 2B), suggesting 
renal excretion of HFn within 1 day. Epf of excised 
tumors 1, 2, 24 and 48 h after AF660-HFn injection 
displayed rapid tumor uptake, which progressively 
decreased in intensity over time (Figure 2C). Confocal 
images acquired on cryosections of excised tumors 
confirmed that HFn reached the 4T1 cell cytoplasm and 
thus were not confined to the tumor stroma or vessels, 
but actively entered into cancer cells (Supplementary 
Figure 4). Combined data reported in Figure 2A-2C 
suggested that a prevalent fraction of nanoparticles that 
were not captured by the tumor were rapidly sequestered 
by the kidneys, and presumably eliminated into the 
bladder. This hypothesis was confirmed by Epf analysis 
of excised kidneys that exhibited a detectable AF660-
HFn fluorescence emission at 1 and 2 h (Figure 2D and 
2E) and further evidence was provided by fluorescence 
measurement of collected urine (Figure 2F). Besides 
kidney filtration, our results suggested preferential 
distribution of HFn in the liver within the first 24 h and 
appreciable Epf was also detected in the spleen for up 
to 2 h. In contrast, HFn were not recovered in the lungs, 
heart and brain (Figure 2D and 2E).
Bioavailability of HFn-DOX and accumulation 
at the tumor
To evaluate the bioavailability of nanoformulated 
drug, 2 groups of healthy mice (5 mice/group) were 
treated with DOX or HFn-DOX at 1.24 mg kg−1. Blood 
samples were collected from the retro-orbital plexus at 15, 
30, 45 and 60 min. These tight time points were chosen to 
detect possible changes in blood bioavailability of DOX or 
HFn-DOX soon after administration, as in both cases the 
drug was injected intravenously. DOX was extracted from 
collected samples and quantified by fluorescence intensity 
analysis (FLI) at λem = 550 nm (λex = 500 nm) [32]. Blood 
samples taken before drug administration were set as 
reference. Bioavailability of HFn-DOX was two-fold 
higher than DOX although the kinetic seems to maintain 
the same shape. To better discriminate kinetic’s variations 
due to nanoformulation, a 10-fold higher dosage of DOX 
or HFn-DOX (i.e. 12.4 mg kg−1) has been administered 
to healthy mice. Results reported in Figure 3A display 
different plasma distribution profiles and confirming that 
HFn-DOX increases drug bioavailability in comparison to 
DOX of at least four-fold at each time point
Accumulation of DOX at primary tumors (Figure 
3B) was determined by fluorescence after chemical 
extraction from homogenates of resected tumors at 1, 2, 
24, and 48 h after single injection of HFn-DOX or DOX 
at 1.24 mg DOX kg−1 [33]. DOX was found in higher 
concentration in tumors of mice treated with HFn-DOX 
compared to DOX within 1 h. HFn-DOX displayed faster 
localization at the tumor compared to DOX, (Figure 
3B), suggesting a crucial role for nanoparticle-mediated 
delivery in enhancing the tumor targeting, although after 2 
h the DOX levels are equilibrated in both cases. Confocal 
images of 4T1-L dissociated from tumors excised at 2 
h evoked higher tumor cell accumulation of DOX in 
samples treated with HFn-DOX compared to DOX (Figure 
3C). Combining these results suggested that HFn-DOX 
were efficiently captured by tumor cells, while DOX was 
confined in blood vessels of the tumor to a much larger 
extent.
Impact of LDNM monotherapy on breast cancer 
management
Eight-week old Balb/C female mice were implanted 
with 4T1-L cells at day 0. Tumor-bearing mice were 
randomly divided into three experimental groups at day 
5 and treated with placebo, DOX, pl-DOX or HFn-DOX 
under our LDNM setting: drug administration (1.24 mg 
DOX kg−1) was performed at day 5, 9, 13 and 17. The 
progression of tumor volume was monitored in vivo 
before each individual drug injection by bioluminescence 
imaging. Images suggested that HFn-DOX could 
decrease tumor growth and metastatic spread (Figure 
4A and Supplementary Table 1). Indeed, while DOX 
displayed a tumor progression similar to the control 
along the experimental window (Figure 4B), HFn-DOX 
could suppress the tumor growth as long as the drug was 
administered (day 17) and exhibited a prolonged effect 
up to the experimental endpoint (day 21). An even better 
effect was achieved with pl-DOX, which was indeed able 
to arrest the tumor development. Immunohistochemical 
analysis of tumor sections showed that the apoptotic effect 
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Figure 2: In vivo targeting and distribution of void HFn nanocarrier. a. Epifluorescence (Epf) images of mice bearing 4T1-L 
tumors acquired 1, 2, 24 and 48 h after intravenous (i.v.) injection into the tail vein of 5 μg kg−1 AF660-HFn and b. averaged Epf intensity 
of the bladder region of interest (ROI). c. Epf of isolated 4T1 tumors and averaged Epf intensity of tumor ROI acquired 1, 2, 24 and 48 h 
after exposure to HFn. d. Epf of isolated spleen (S), kidneys (K), liver (L), brain (B), heart (H), lungs (Lu), and e. averaged Epf intensity 
of the ROI obtained after 1, 2, 24 and 48 h exposure to HFn. f. Fluorescence intensity of urine collected 1, 2, 24 and 48 h after i.v. injection 
of AF660-HFn. The color scale in panels a, c and d indicates the averaged epifluorescence expressed as radiant efficiency [(p/sec/cm2/sr)/
(mW/cm2)], where p/sec/cm2/sr is the number of photons per second that leave a square centimeter of tissue and radiate into a solid angle of 
one steradian (sr). Values reported in panels b, c, e and f are mean ± SE of at least 4 different samples under each experimental condition.
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of pl-DOX and HFn-DOX on BC cells was better than 
that of DOX (Figure 4C and Supplementary Figure 5), 
presumably due to the improved tumor accumulation of 
the drug. However, the absence of statistical significance 
in apoptosis between HFn-DOX and DOX treated samples 
advocated alternative factors in the stronger antitumor 
efficacy of HFn-DOX beyond mere cytotoxicity.
Impact of LDNM regimen on tumor angiogenesis 
and chemoresistance
In line with the observed discrepancy in the results 
from the DNA fragmentation assay (Figure 4C), we 
investigated the possible involvement of anti-angiogenic 
effect of HFn-DOX under the LDNM regimen. Vessel 
labeling with anti-CD31 antibody in BC histological 
Figure 3: Bioavailability and tumor accumulation of HFn-DOX in comparison with free DOX. a. Bioavailability of 
DOX and HFn-DOX at different time points. Plasma concentration of DOX after i.v. injection of HFn-DOX (black circles) or DOX (gray 
triangles) at 1.24 mg kg−1 and 12.4 mg kg−1 in healthy mice. b. DOX accumulation at 4T1-L tumor in mice at different time points after 
administration of 1.24 mg kg−1 DOX as free molecule or HFn-DOX. Female Balb/C mice orthotopically implanted with 4T1-L murine 
mammary carcinoma cells were injected 6 days after implantation (time 0) with DOX or HFn-DOX. DOX levels in tumor have been 
determined 1, 2, 4, and 24 h after i.v. injection following acidified isopropanol extraction from tumor homogenates. Aliquots from six mice 
per each time point concentration have been extracted and analyzed by spectrofluorimeter. Reported values are means of 3 samples/group 
± SE. P values are summarized in Table S5. c. Confocal microscopy images of 4T1-L cells dissociated from tumor harvested 2 h after i.v. 
injection of DOX and HFn-DOX. DOX signal is represented in green, while nuclei were stained with DAPI (blue). Scale bar: 10 μm.
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slides revealed a remarkable decrease in the number of 
CD31-positive cells compared to DOX (Figure 5A and 
Supplementary Figure 6), suggesting a role of the HFn-
DOX-promoted antiangiogenic effect on the inhibition 
of tumor progression and diffusion. Analogously, it is 
likely that the strong inhibition in tumor growth observed 
with pl-DOX (Figure 4B) was primarily due to anti-
angiogenic activity (Figure 5A). 4T1-L BC cells have 
been described to develop drug resistance owing to 
induced overexpression of MDR-1 protein upon standard 
treatment with DOX [28]. Western blot performed on 4T1 
cells treated for 72 h with 0.1 μM DOX corroborated DOX 
induction of MDR-1 expression in vitro (Supplementary 
Figure 7). We examined MDR-1 expression in tumor 
tissues dissected after LDNM treatment. Tumor sections 
from DOX and pl-DOX-treated mice displayed a 
three-fold and five-fold increase in MDR-1-positive 
cells, respectively, compared to animals treated with 
placebo and HFn-DOX treated animals (Figure 5B and 
Supplementary Figure 8). As expected, both DOX and 
pl-DOX induced an obvious overexpression of MDR-1 in 
tumor cell membranes, which was particularly pronounced 
in the proximity of the tumor endothelium [34]. In 
contrast, MDR-1 expression was undetectable in tumor 
cell membranes after HFn-DOX treatment and was found 
only to a limited extent in tumor vessels after HFn-DOX 
Figure 4: Efficacy of LDNM treatment with HFn-DOX. a. DOX and HFn-DOX in vivo efficacy. Bioluminescence imaging of 
female Balb/C mice (n = 12/group) orthotopically implanted (day 0) with 4T1-L murine mammary carcinoma cells were treated with 
placebo or with 1.24 mg kg−1 of DOX, pl-DOX or HFn-DOX. Drug injections were performed into the tail vein at day 5, 9, 13 and 17. Mice 
were sacrificed at day 21. b. Quantification of tumor volume. Tumor volume was quantified by measuring the bioluminescence intensity 
signal of 4T1-L cells 5 min after intraperitoneal injection of luciferin. Dots represent the normalized mean value of BLI tumor signal ± 
SE. Statistical significance vs. placebo #P<0.05 ###P<0.005; vs. DOX *P<0.05 ***P<0.005. c. Quantification of apoptosis in tumor tissue 
upon treatment with HFn-DOX. Tumors excised at day 21 (n = 6/group) were fixed with formalin and embedded in paraffin. Histological 
slides were processed to label DNA fragments of apoptotic cells. Reported values are the mean of apoptotic cells number/field/sample ± SE. 
The count was performed on 10 fields/sample. Magnification 20×. Statistical significance vs. placebo ###P<0.005; vs. DOX ***P<0.005.
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treatment, at the same level of the placebo. This result is 
relevant in view of a protracted metronomic treatment 
preventing the onset of chemoresistance, and it is even 
more surprising considering that pl-DOX is commonly 
used in patients previously treated with anthracyclines and 
therefore affected by potentially chemoresistant cancers.
HFn-DOX suppresses DOX cardiotoxicity and 
systemic dysfunction under a LDNM therapeutic 
setting
Cardiotoxicity represents a life-threatening 
unresolved issue associated to DOX chemotherapy under 
clinically relevant settings [35]. To evaluate the incidence 
of LDNM monotherapy on cardiotoxicity, we followed a 
multiparametric approach [36]. First, histological slides 
of heart tissues were treated with FITC-conjugated wheat 
germ agglutinin (FITC-WGA), a cell membrane label, 
and imaged by fluorescence microscopy (Supplementary 
Figure 9). Cardiomyocyte cross-sections from mice 
treated with HFn-DOX, pl-DOX, DOX or non-treated 
were measured at day 21. Images showed a significant 
increase of cardiomyocyte area in DOX and pl-DOX 
samples suggesting a strong cellular damage response 
compared to HFn-DOX samples (Figure 6A). Detailed 
ultrastructural analysis of cardiac cells in DOX and pl-
DOX treated samples revealed an increased number 
of mitochondria compared to HFn-DOX (Figure 6B 
and Supplementary Figure 10). In addition, changes in 
mitochondria morphology, including larger surface area 
and cristae depletion, typical effects of DOX-induced 
cardiomyopathy [36], were clearly evident in DOX and 
pl-DOX treated samples but not in HFn-DOX samples 
(Figure 6C-6E). Therefore, the absence of obvious 
alterations in mitochondria number and morphology in 
heart samples from mice treated with HFn-DOX strongly 
supports the lack of cardiotoxicity in LDNM HFn-DOX 
treatment, even compared to pl-DOX, which is currently 
considered the most safe anthracycline therapy in terms of 
cardiotoxicity.
To further investigate if the ultrastructural 
alterations were associated to mitochondrial dysfunction, 
mitochondria isolated from heart tissue of DOX, pl-DOX 
or HFn-DOX treated mice were analyzed in detail. The 
membrane potential decreased by 30% in DOX and pl-
DOX samples compared to HFn-DOX (Figure 6F). As 
mitochondrial impairment was expected to generate 
reactive oxygen species (ROS) [37], we quantified the 
level of the ROS quencher glutathione (GSH) in heart 
tissue [38]. Figure 6G displays the lower amount of 
reduced GSH in DOX and pl-DOX-treated mice in 
comparison to HFn-DOX, confirming mitochondrial 
dysfunction induced by treatment with free and liposomal 
DOX only.
Finally, we assessed the systemic toxicity of 
HFn-DOX by histopathological examination of liver, 
kidneys, lung, spleen, heart, gut and brain isolated 
at day 21. No histological lesions were found in all 
organs (Supplementary Figure 11). Liver and kidney 
functionalities were also determined to further evaluate 
the toxicity profile of HFn-DOX treatment. Serum levels 
of aspartate transaminase (AST) and alanine transaminase 
(ALT) (Supplementary Table 2), and urea and creatinine 
Figure 5: Impact of LDNM regimen on tumor 
angiogenesis and chemoresistance. a. Quantification of 
angiogenesis in tumor tissue upon treatment with HFn-DOX. 
Tumors excised at day 21 (n = 5/group) were fixed with formalin 
and embedded in paraffin. Immunohistochemistry of histological 
slides were processed to label CD31+ cells. Reported values 
are mean of vessel number counted in 10 fields/sample ± 
SE. Magnification 40×. Statistical significance vs. placebo 
#P<0.005 ###P<0.00005; vs. DOX ***P<0.00005; vs. pl-DOX 
§§§P<0.0005. b. Quantification of MDR-1-expression. Excised 
tumors (n = 5/group) were processed for immunohistochemistry 
of MDR-1 antigen. The percentage of image area positive 
for MDR-1 expression was quantified using ImagePro Plus 
Software. Reported values are the mean of the percentage 
of MDR-1 positive signal counted in 5 fields/sample ± SE. 
Statistical significance vs. Placebo ##P<0.0005 ###P<0.00005; 
vs. DOX **P<0.005 ***P<0.0005; vs. pl-DOX §§§P<0.0005.
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Figure 6: Examination of cardiotoxicity of HFn-DOX, pl-DOX and DOX. a. Nanodelivery protects cardiomyocytes from DOX-
induced hypertrophy. Hearts excised at day 21 (n = 3/group) from mice treated with placebo or with 1.24 mg kg−1 of DOX, pl-DOX or HFn-
DOX were fixed with formalin and embedded in paraffin. Histological slides of cardiac sections stained with FITC-WGA were analyzed 
with ImageJ software to measure cross-section area of cardiomyocytes. Quantification was performed on at least 5 images/group, reporting 
the mean value of cross-section area of 250 cells/group± SE. Statistical significance vs. Placebo ###P<0.00005; vs. DOX ***P<0.00005; vs. 
pl-DOX §§§P<0.00005. b. Nanodelivery protects against DOX-induced mitochondrial toxicity. Hearts excised at day 21 (n = 3/group) from 
mice treated with placebo or with 1.24 mg kg−1 of DOX, pl-DOX or HFn-DOX were fixed with glutaraldehyde and embedded in epoxy-resin. 
TEM images of ultrathin heart sections of cardiac tissues acquired at 4200 magnifications were analyzed with ImageJ to measure the number of 
mitochondria in heart tissue. Quantification was performed on at least 9 images/group, reporting the mean mitochondria number/image ± SE. 
Statistical significance vs. Placebo ###P<0.00005; vs. DOX ***P<0.00005 *P<0.005; vs. pl-DOX §§§P<0.00005. c. Representative images 
of hearts excised at day 21 (n = 3/group) from mice treated with placebo or with 1.24 mg kg−1 of DOX, pl-DOX or HFn-DOX. TEM images of 
ultrathin heart sections of cardiac tissues have been acquired at 11500 magnifications. d. Nanodelivery reduces the mitochondrial size growth 
due to DOX treatment. Quantification of TEM images (ImageJ) of ultrathin heart sections acquired at 11500 magnifications. Quantification 
was performed on at least 10 images/group, measuring at least 100 mitochondria/sample. Values represent the mean mitochondrial area 
± SE. Statistical significance vs. Placebo ###P<0.00005 #P<0.05; vs. DOX ***P<0.00005; vs. pl-DOX §§§P<0.00005. e. Nano delivery 
limits the damage of mitochondrial cristae from DOX. Quantification of TEM images (Image J) of ultrathin heart sections acquired at 11500 
magnifications. Quantification was performed on at least 10 images/group, measuring at least 100 mitochondria/sample. Values represent the 
percentage of mitochondrial area occupied by cristae ± SE. Statistical significance vs. Placebo ###P<0.00005; vs. DOX ***P<0.00005; vs. 
pl-DOX §§§P<0.00005 f. HFn-DOX does not affect mitochondrial membrane potential. Mitochondrial membrane potential was measured 
by staining-isolated mitochondria from mouse heart tissue dissected at day 21 (n = 3/group) from mice treated with placebo or with 1.24 
mg kg−1 of DOX, pl-DOX or HFn-DOX. Statistical significance vs. Placebo #P<0.05; vs. pl-DOX §P<0.05. g. HFn-DOX does not decrease 
the concentration of reduced GSH. The extent of reduced GSH was measured in lysates of hearts excised at day 21 (n = 3/group) from mice 
treated with placebo or with 1.24 mg kg−1 of DOX, pl-DOX or HFn-DOX. Values represent the mean GSH concentration in heart extracts± SE. 
Statistical significance vs. Placebo #P<0.05; vs. pl-DOX §P<0.05.
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(Supplementary Table 3), were monitored as markers 
of liver and kidney condition, respectively. Our results 
showed that AST/ALT and urea/creatinine ratios in HFn-
DOX treated mice were comparable to the control and in 
the range of reference, confirming the overall nanodrug 
safety.
DISCUSSION
In the present study a highly aggressive metastatic 
BC model based on murine 4T1 cells was established. 
This allowed us to simulate the dramatic clinical picture 
of advanced BC patients and to evaluate the impact of 
DOX nanoformulation under LDM monotherapy in 
compromised subjects, as DOX remains a mainstay 
therapy in various solid tumors. Our results suggest that 
DOX monotherapy does not affect tumor progression 
significantly: although the expected cytotoxicity was 
confirmed in vitro, this did not translate into substantial 
antitumor activity in vivo in an advanced-stage BC model, 
whereas off-target tissue accumulation and myocardial 
damage largely occurred. This result is reminiscent of the 
frustrating clinical condition in which chemotherapy fails 
to overcome BC progression and combination therapies 
become necessary to control the disease. Therefore, the 
potential of LDM DOX to overcome the limitations of 
dose-dense regimens in advanced-stage tumors remains 
questionable, since DOX requires high doses to gain a 
proper drug concentration at cancer deposits [39–40]. 
In contrast, the results of our study demonstrate that our 
LDNM strategy, which combines LDM administration 
of DOX with HFn-delivery resulted in a targeted effect 
of DOX on 4T1 cancer cells together with a sustained 
antiangiogenic activity in the tumor microenvironment. 
Indeed, HFn-DOX exhibited potent antitumor activity 
when administered at frequent doses as low as 1.24 
mg kg−1 in vivo compared to free DOX and placebo. 
Such a strongly improved activity correlates with the 
pharmacokinetic profile of LDNM DOX, as emerged 
from a recent biodistribution study [41]. Indeed, while 
DOX displayed reduced bioavailability, high levels of 
HFn-DOX were recovered in plasma during the first 
few hours post-injection that were attributable to a lower 
sequestration by off-target organs [41]. HFn-DOX could 
accumulate in the tumor site exploiting the EPR effect 
[42] or by endothelial wall transcytosis promoted by TfR-
1 recognition [43] and it is internalized in tumor cells 
by receptor-mediated endocytosis [44]. HFn-mediated 
target selectivity conferred earlier intra-tumor activity 
to the drug, lower off-target accumulation with fast liver 
metabolism and rapid clearance of circulating excess 
drug by renal excretion, suggesting optimal therapeutic 
index in future clinical translation [41, 44]. Beyond its 
favorable bioavailability and target selectivity, a plausible 
explanation for enhanced antitumor activity of LDNM 
HFn-DOX resides in HFn propensity to behave like a 
Trojan horse, imparting DOX with drastically enhanced 
nuclear penetration even in resistant cancer cells [25, 45]. 
Such HFn property can greatly improve current strategies 
of LDM chemotherapy, due to sustained nuclear release of 
a DNA-damaging drug. Indeed, our in vitro experiments 
showed that HFn-mediated delivery allowed a 15.2-fold 
increase of DOX nuclear concentration within 3 h as 
compared to the drug alone.
Even drug resistance significantly impacts on BC 
management, accounting for a relevant proportion of 
patients in which anthracycline therapy fails to persistently 
eradicate the tumor [46]. MDR-1 protein is one of the 
most active multidrug resistance mediators in BC and it 
is gradually overexpressed under DOX chemotherapy 
regimens [28]. Negligible MDR-1 induction in tumor 
cells in vivo after LDNM DOX administration suggested 
that the multidrug resistance machinery of BC cells did 
not “sense” the cytotoxic agent in HFn-DOX. Otherwise, 
the dramatic increase of MDR-1 expression observed in 
samples from mice treated with DOX and even with pl-
DOX, suggested that LDNM administration associated 
with cell nuclear targeting could circumvent DOX 
resistance dependent by MDR-1.
The general assumption that LDM therapy is 
essentially due to inhibition of angiogenesis, rather 
than directly killing residual cancer cells [8], should be 
reconsidered in the framework of LDNM regimen, in 
which a key role of targeted action could be reappraised. 
Combining our data from angiogenesis inhibition with the 
results from tumor progression (i.e BC growth curves and 
DNA fragmentation assay) we concluded that targeted 
action of HFn-DOX on BC cells and antiangiogenic effect 
of LDNM regimen could play a synergistic role in the 
increased antitumor efficacy of HFn-DOX compared to 
DOX alone.
Importantly, LDNM chemotherapy exhibited a safe 
toxicity profile, as proven by apparent lack of systemic 
side effects. This is expected to have great clinical impact 
because cardiotoxicity and general side effects lead to 
major restriction in the clinical use of anthracyclines. 
HFn-DOX was less cardiotoxic compared to DOX and 
even to pl-DOX, although the latter has been associated 
with improved cardiac safety in various clinical studies. 
Nevertheless, myocardial alterations provoked by pl-DOX 
(Figure 6) are not surprising. Indeed, a certain degree of 
myocardial damage has been previously demonstrated 
in endomyocardial biopsies of patients treated with pl-
DOX, and ultrastructural damage of pl-DOX has not 
been explored [38, 47]. Moreover, although pl-DOX 
is less cardiotoxic, it does not significantly reduce 
relevant cardiac events, and a clinician’s preference 
for pl-DOX over conventional DOX to avoid clinically 
significant cardiac events is not justified in patients 
without concurrent cardiac disorders that were not 
previously subjected to anthracycline exposure [48]. 
Therefore, the general confidence on low cardiotoxicity 
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of pl-DOX should be reconsidered in the light of these 
considerations. Otherwise, LDNM treatment with HFn-
DOX didn’t display anthracycline-related cardiotoxicity, 
even in comparison with pl-DOX, and it is therefore a 
promising option for anthracycline therapeutic regimens 
in cardiosensitive subjects.
We acknowledge a potential limitation relating to 
immunogenicity in clinical translation of HFn-DOX [49]. 
Although it is difficult to predict the long-term effect 
of prolonged treatments in humans, we have collected 
preliminary data suggesting negligible immunogenicity 
of HFn in animals. Another limitation of the study 
is the experimental timespan limited to three weeks. 
However, based on our findings we could postulate that 
after 21 days the metronomic treatment by HFn-DOX 
would lead to further reduction of cancer deposits, as 
expected by the excellent cytotoxicity showed by HFn-
DOX in vitro. Moreover, the fact that MDR-1 expression 
remained stable over time upon treatment with HFn-DOX 
suggests avoidance of chemoresistance, thus a sustained 
anticancer activity even after 21 days is expected. About 
cardiotoxicity, our findings suggest that substantially 
no myocardial damage is present after treatment with 
HFn-DOX, and we should expect the same lack in 
cardiotoxicity even after experimental timespan.
In summary, this study provides robust evidence 
that LDNM monotherapy with HFn-DOX is expected to 
remodel the therapeutic outcome of advanced metastatic 
BC compared to the drug alone and also to improve 
anthracycline therapies based on liposomal DOX, 
with a redefinition of the central role of DOX for solid 
malignancies under the new perspective of metronomic 
treatments. Further investigations are necessary to 
thoroughly elucidate the individual contributions of 
targeted therapy and neoangiogenesis inhibition in the 
strong enhancement of the antitumor efficacy of HFn-
DOX. On the horizon after this study is the possibility of 
countless developments, one of which is a reappraisal of 
current clinical settings by combining low toxic LDNM 
regimens with administration of established antiangiogenic 
agents.
MATERIALS AND METHODS
Cell cultures and in vitro studies
Murine Bioware-Ultra 4T1-Luc2 cell line (4T1-L), 
used as model of BC cells, have been purchased in 2011 
from Perkin Elmer, confirmed by IMPACT I PCR profiling 
by the source, and have been passaged for fewer than 6 
months. 4T1-L were cultured in RPMI 1640 medium 
supplemented with 10% foetal bovine serum, 2 mM 
l-glutamine, penicillin (50 UI mL−1) and streptomycin (50 
mg mL−1) at 37 °C in humidified atmosphere containing 
5% CO2 and sub-cultured prior to confluence using 
trypsin/EDTA. 4T1 cells, were used for in vitro tests 
and orthotopically implanted at passages lower than 4 in 
female Balb/C mice to obtain the BC animal model.
Details of HFn-DOX production, cell binding, 
proliferation, death and DNA damage assays, intracellular 
localization by confocal laser scanning microscopy, are 
provided in the Supplementary Materials and Methods.
Study design
The hypothesis was that HFn-DOX would exhibit 
higher antitumor efficacy and would induce minimal 
or negligible side effects compared to free drug and pl-
DOX (Caelyx) in mice bearing strongly invasive and 
metastatic BC. HFn-DOX dose was set at 1.24 mg kg−1 
DOX, about 1/7 of the average MTD dosage administered 
in 4T1 murine BC [26]. This tumor model was selected 
for its aggressiveness and spontaneous tendency to spread 
to multiple metastatic sites after orthotopic injection 
of luciferase-tagged cells. The endpoint of the in vivo 
experiments was defined at 21 days to appreciate the 
parametric differences in tumor growth, resistance onset 
and cardiotoxicity in living animals, while allowing us 
to operate in compliance with the National and European 
legislations that regulate animal experiments. The number 
of animals for each biodistribution, bioavailability, therapy 
and cardiotoxicity experiment was calculated with a power 
of at least 80 ± 5 %. Mice were randomized by primary 
tumor size before initiation of treatments. Dye-labeled 
HFn was first injected in tumor-bearing mice by tail vein, 
then targeting and biodistribution were assessed by live 
fluorescence imaging, while drug bioavailability was 
evaluated in healthy animals. Rodents were administered 
intravenously with placebo, DOX, pl-DOX or HFn-DOX 
at day 5, 9, 13 and 17, and monitored for 21 days during 
which tumor growth was followed by measurement of 
bioluminescence signal intensity (BLI) of 4T1-L cells 
after intraperitoneal injection of luciferin. BLI analyses 
were undertaken under standardized conditions to gain a 
quantitative estimation of live BC cells. Intermediate BLI 
values and mouse weights were determined before each 
administration. Collected BLI data were normalized to 
the mean tumor size calculated for all mice within each 
group at each time point. Animals were euthanized at day 
21 to analyze resected tissues with the aim of determining 
the antitumor efficacy, anti-angiogenic activity and 
cardiotoxicity of DOX, pl-DOX and or HFn-DOX. 
Histopathology and immunohistochemistry were analyzed 
from blinded samples. Outliers were not excluded. All 
experiments were conducted under an approved protocol 
of the Italian Ministry of Health. Animals were cared 
for according to the guidelines of the Italian Ministry of 
Health (see the Supplementary Materials and Methods).
In vivo experiments
Details of the preparation of orthotopic 4T1 model, 
tumor cell injection, tumor imaging, targeting and 
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biodistribution, plasma half-life, drug accumulation at 
the tumor of DOX and HFn-DOX and antitumor in vivo 
efficacy of DOX, pl-DOX or HFn-DOX are provided in 
Supplementary Materials and Methods.
Ex vivo analyses
Excised tumors were analyzed by fluorescence 
imaging and by confocal microscopy of cryosections 
to establish the HFn cellular targeting in vivo, 
immunofluorescence of dissociated tumor to assess DOX 
accumulation, immunohistochemistry to determine the 
CD31 and MDR-1 expression in endothelial and tumor 
cells, respectively, and Tumor TACS In Situ Apoptosis 
Detection kit to determine cellular apoptosis. Excised 
organs were analyzed by fluorescence imaging to 
establish the HFn biodistribution in non-target organs. 
Histopathology was performed on samples from liver, 
kidneys, spleen, heart, brain, gut and lung tissues. 
Kidney and liver functionality was assessed before and 
after the treatment. The size of cardiomyocytes extracted 
from resected heart tissues was measured after wheat 
germ agglutinin (WGA) fluorescence labeling. Isolated 
mitochondria from heart tissue samples were investigated 
by membrane potential and ultrastructural analysis of 
transmission electron micrographs; the extent of ROS 
in heart was assessed by glutathione assay. Details are 
reported in Supplementary Materials and Methods.
Statistical analysis
Statistical analyses were conducted using two-tailed 
Student’s t-test. All plots show mean values ± SE. All tests 
assumed normal distribution and the statistical significance 
threshold was set at P< 0.05
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